2-Ethoxy-5,7-dimethyl-3-[{2'-(1H-tetrazol-5-yl)biphenyl-4-yl}methyl]-3H-imidazo[4,5-b]pyridine | 135070-02-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Ethoxy-5,7-dimethyl-3-[{2'-(1H-tetrazol-5-yl)biphenyl-4-yl}methyl]-3H-imidazo[4,5-b]pyridine
• 英文别名: 2-ethoxy-5,7-dimethyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazo[4,5-b]pyridine
• CAS: 135070-02-9
• 化学式: C₂₄H₂₃N₇O
• 分子量: 425.493
• InChiKey: GDMQZOKKDMGAMM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  94.4
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Biphenylmethane derivative, the use of it and pharmacological compositions containing same
  申请人：Eisai Co., Ltd.

  公开号：EP0420237A1

  公开（公告）日：1991-04-03

  The biphenylmethane derivative having the formula (I) is disclosed

  公开了具有式 (I) 的联苯甲烷衍生物
• Biphenylmethane derivatives, the use of them and pharmacological compositions containing same
  申请人：Eisai Co., Ltd.

  公开号：EP0628557A1

  公开（公告）日：1994-12-14

  Disclosed are biphenylmethane derivatives having the formula:    wherein    R² and R³, which may be the same or different, are each a hydrogen atom, a halogen atom, a lower C₁₋₆ alkyl group a lower C₁₋₆ alkoxy group, a carbamoyl group or a cyano group;    R⁴ stands for hydrogen or a lower C₁₋₆ alkyl group;    R⁵ is 1H-tetrazol-5-yl, a carboxyl (-COOH) group or a carboxylic ester thereof;    R⁶ stands for hydrogen, a halogen atom, a hydroxy group or a lower C₁₋₆ alkoxy group, or a pharmacologically acceptable salt thereof,    wherein    compounds having the following formula and their pharmacologically acceptable salts are excluded:    wherein R⁵ is 1H-tetrazol-5-yl, a carboxyl (-COOH) group or a carboxylic ester thereof and n is an integer of 1 to 2;    or a pharmacologically acceptable salt thereof. Further, a process for their preparation, pharmaceutical compositions containing same and their use for the preparation of such compositions for preventing and treating hypertension and/or cardiac failure are disclosed.

  所公开的是具有以下式子的联苯甲烷衍生物： 其中 R²和R³可以相同或不同，各自为氢原子、卤素原子、低级C₁₋₆烷基、低级C₁₋₆烷氧基、氨基甲酰基或氰基； R⁴ 代表氢或低级 C₁₋₆ 烷基； R⁵ 是 1H-四唑-5-基、羧基 (-COOH) 或其羧酸酯； R⁶ 代表氢、卤素原子、羟基或低 C₁₋₆ 烷氧基，或其药理学上可接受的盐、 其中 具有下式的化合物及其药理学上可接受的盐除外： 其中 R⁵ 是 1H-四唑-5-基、羧基（-COOH）或其羧酸酯，n 是 1 至 2 的整数； 或其药理学上可接受的盐。 此外，还公开了它们的制备工艺、含有它们的药物组合物以及制备这种组合物用于预防和治疗高血压和/或心力衰竭的用途。
• MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS
  申请人：BARLOW Carrolee

  公开号：US20110046090A1

  公开（公告）日：2011-02-24

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a GABA agent or GABA analog, in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.
• NEUROGENESIS BY MODULATING ANGIOTENSIN
  申请人：BARLOW Carrolee

  公开号：US20110269717A1

  公开（公告）日：2011-11-03

  The instant invention describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The invention includes compositions and methods based on modulating angiotensin activity to stimulate or activate the formation of new nerve cells.
• US5298518A
  申请人：——

  公开号：US5298518A

  公开（公告）日：1994-03-29